Savitz Ryan 4

What Happened
Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics (DNTH), exercised 31,249 stock options on July 9, 2026 (exercise price $21.77, total cost $680,291) and sold the 31,249 resulting shares the same day in open-market transactions for total gross proceeds of about $3,157,151. The sale proceeds minus the exercise cost equal roughly $2,476,860 in net proceeds.

Key Details

• Transaction date: July 9, 2026; Form 4 filed July 13, 2026 (filed within the required 2 business days).
• Exercise: 31,249 shares acquired at $21.77 each for $680,291.
• Sales (open market, three blocks):
  • 10,354 shares at a weighted avg $100.22 (range $99.75–$100.74) — $1,037,678
  • 15,329 shares at a weighted avg $101.24 (range $100.78–$101.75) — $1,551,908
  • 5,566 shares at a weighted avg $101.97 (range $101.95–$102.15) — $567,565
  • Total shares sold: 31,249; total gross proceeds: ~$3.16M
• The filing shows a related derivative disposition line for 31,249 shares at $0.00 reflecting conversion/exercise of the option instrument.
• Footnotes: sales were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 30, 2025. Option award vests in equal monthly installments over four years after May 1, 2024.
• Shares owned after the transactions are not disclosed in the provided excerpt of the filing.

Context

• This was an exercise of options followed by immediate open-market sales (a common cashless or sell-to-cover pattern). The reporting distinguishes the option conversion (derivative) and the subsequent open-market sales.
• Sales executed under a 10b5-1 plan indicate they followed a pre-arranged trading schedule; such plans are commonly used to avoid timing questions but do not by themselves indicate sentiment.
• All amounts above are from the Form 4; the filing is timely based on the transaction and filing dates.